ELI LILLY AND COMPANY Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest
ELI LILLY AND COMPANY (LLY) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest of $11.00 million for the 12-month period ending 2018-12-31, per its 8-K filed 2019-10-24.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest · last filed 2019-10-24
- ELI LILLY AND COMPANY other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2017-12-31 was -$11.10M.
- ELI LILLY AND COMPANY other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2017-09-30 was $2.20M.
- ELI LILLY AND COMPANY other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2017-06-30 was -$4.60M.
- ELI LILLY AND COMPANY other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2017-03-31 was -$11.00M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2018-12-31 | $11.00M 8-K · filed 2019-10-24 | |||
| 2017-12-31 | -$11.10M derived: 8-K 12 month − 10-Q 9 month · filed 2019-10-24 | -$8.90M derived: sum of 2 quarters · filed 2019-10-24 | -$13.50M derived: sum of 3 quarters · filed 2019-10-24 | -$24.50M 8-K · filed 2019-10-24 |
| 2017-09-30 | $2.20M 10-Q · filed 2018-11-06 | -$2.40M derived: sum of 2 quarters · filed 2018-11-06 | -$13.40M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | -$4.60M 10-Q · filed 2018-07-25 | -$15.60M 10-Q · filed 2018-07-25 | ||
| 2017-03-31 | -$11.00M 10-Q · filed 2018-04-27 | |||
| 2016-12-31 | $48.20M 8-K · filed 2019-10-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |